# Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

> **NCT00193258** · PHASE1,PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 94 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00193258
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2011-01
- **Final completion:** 2011-08
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2013-01-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193258, "Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00193258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*